NKCC1 Inhibitor Program
Autism, Epilepsies, and other CNS disorders
Phase 1Active
Key Facts
Indication
Autism, Epilepsies, and other CNS disorders
Phase
Phase 1
Status
Active
Company
About IAMA Therapeutics
IAMA Therapeutics is a private, clinical-stage biotech company pioneering a novel approach to treating central nervous system (CNS) disorders through the selective inhibition of cation-chloride cotransporters, with a primary focus on NKCC1. The company, a spin-off from the Istituto Italiano di Tecnologia, has secured significant funding (€15M in 2025) and is led by an experienced CEO, Torsten M. Madsen, appointed in late 2025. IAMA's strategy is to restore neuronal balance by modulating chloride transport, targeting high-unmet-need conditions like autism and epilepsy where current treatments are often inadequate.
View full company profile